Investigational drug · Phase 2
SAR443122
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Colitis Ulcerative.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "SAR443122"
First trial start
2022
Nov 25, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SAR443122", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colitis Ulcerative
Largest trials
Live from ClinicalTrials.gov: studies naming "SAR443122" as an intervention, largest first.
- Dose-finding Study of SAR443122 in Adult Participants With Ulcerative ColitisPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT05588843 · 187 participants · Start Nov 25, 2022 · Primary completion Feb 10, 2026
Drug: SAR443122; Placebo · For: Colitis Ulcerative
Sites: Lancaster, California; Atlanta, Georgia; Evanston, Illinois · 106 sites in all
SanofiSanofi (SNY)
NCT04781816 · 78 participants · Start Apr 1, 2021 · Primary completion May 25, 2023
Drug: SAR443122; Placebo · For: Cutaneous Lupus Erythematosus
Sites: Cooper City, Florida; Charlotte, North Carolina; Columbus, Ohio · 50 sites in all
- A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19Completed
SanofiSanofi (SNY)
NCT04469621 · 68 participants · Start Jul 17, 2020 · Primary completion Oct 23, 2020
Drug: SAR443122; Placebo · For: Corona Virus Infection
Sites: Caba, Argentina; Porto Alegre, Brazil; São José do Rio Preto, Brazil · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
Also in development for Colitis Ulcerative
- MK-8690PRA052Phase 21 trial
Merck & Co. · Colitis Ulcerative, Ulcerative Colitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.